Healthcare / BiotechnologyMCE
$16.15
+0.15 (+0.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $640241.72 · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
62/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$121M
P/E
41.4x
↑EV/EBITDA
28.9x
↑ROE
28.1%
↑Gross Margin
105.5%
↑Debt/Equity
0.19
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+31.5%
FCF CAGR
—
FCF margin
14.6%
FCF / Net income
0.42x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.4M · net income $2.9M · FCF $1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.4M | $8.4M | $5.0M | $3.7M | $3.7M |
| Net Income | $2.9M | $2.9M | $1.0M | $544943.40 | $605257.19 |
| EBITDA | $4.2M | $4.2M | $1.8M | $1.2M | $1.3M |
| EPS | — | — | — | 0.08 | 0.09 |
| Gross Margin | 105.5% | 105.5% | 109.0% | 116.4% | 112.2% |
| Operating Margin | 38.0% | 38.0% | 19.9% | 12.2% | 17.5% |
| Net Margin | 34.6% | 34.6% | 20.2% | 14.6% | 16.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.19 | 0.19 | 0.34 | 0.54 | 0.43 |
| Current Ratio | 3.03 | 3.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.2M | $1.2M | $640241.72 | $-261833.56 | $-268618.80 |
| Returns | |||||
| ROE | 28.1% | 28.1% | 14.0% | 10.3% | 12.7% |
| Valuation | |||||
| P/E | 41.41 | 41.41 | — | 40.54 | 37.09 |
| EV/EBITDA | 28.87 | 28.87 | 8.83 | 20.22 | 17.77 |
| P/B | 11.78 | 11.78 | 2.23 | 4.17 | 4.72 |
| Growth & Yield | |||||
| Revenue Growth | 66.0% | 66.0% | 35.0% | 1.5% | — |
| EPS Growth | — | — | — | -8.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+295.8%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+295.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.